. 2021 Jul 14;29(1):14–27. doi: 10.1038/s41418-021-00828-6

Table 1.

Correlation between CDK15 expression and clinicopathological characteristics of CRC.

Characteristics	CDK15 expression
Gender
Male Female	21 (50.00%) 21 (50.00%)	22 (52.38%) 20 (47.62%)	>0.9999
Age
≤60 >60	8 (19.05%) 34 (80.95%)	9 (21.43%) 33 (78.57%)	>0.9999
Tumor size
≤5 cm >5 cm	29 (69.05%) 13 (30.95%)	25 (59.52%) 17 (40.48%)	0.4949
Histological grade
Well/moderately Poorly	38 (90.48%) 4 (9.52%)	33 (78.57%) 9 (21.43%)	0.2268
pT status
T1 + T2 T3 T4	3 (7.32%) 31 (75.61%) 7 (17.07%)	3 (7.14%) 33 (78.57%) 6 (14.29%)	0.9383
pN status
N0 N1 N2	31 (73.81%) 11 (26.19%) 0 (0%)	21 (50.0%) 13 (30.95%) 8 (19.05%)	0.0064
Clinical stage
I II III	3 (7.32%) 28 (68.29%) 10 (24.39%)	3 (7.14%) 18 (42.86%) 21 (50%)	0.0482

Characteristics

CDK15 expression

Low (n = 42)

High (n = 42)

Gender

Male

Female

21 (50.00%)

22 (52.38%)

20 (47.62%)

>0.9999

Age

≤60

>60

8 (19.05%)

34 (80.95%)

9 (21.43%)

33 (78.57%)

>0.9999

Tumor size

≤5 cm

>5 cm

29 (69.05%)

13 (30.95%)

25 (59.52%)

17 (40.48%)

0.4949

Histological grade

Well/moderately

Poorly

38 (90.48%)

4 (9.52%)

33 (78.57%)

9 (21.43%)

0.2268

pT status

T1 + T2

3 (7.32%)

31 (75.61%)

7 (17.07%)

3 (7.14%)

33 (78.57%)

6 (14.29%)

0.9383

pN status

31 (73.81%)

11 (26.19%)

0 (0%)

21 (50.0%)

13 (30.95%)

8 (19.05%)

0.0064

Clinical stage

III

3 (7.32%)

28 (68.29%)

10 (24.39%)

3 (7.14%)

18 (42.86%)

21 (50%)

0.0482

All data are the number of patients (%).

Numbers do not equal to the total number due to missing data.